Neurology of Central FL Res Ctr | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Relapsing Multiple Sclerosis	Recruiting	Phase 3	2026-08-26		NCT06846281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)	Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence	Active, not recruiting	Phase 3	2026-08-18		NCT05147220
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab	Relapsing Multiple Sclerosis (RMS)	Active, not recruiting	Phase 3	2026-08-10		NCT06869785
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Recruiting	Phase 3	2026-07-29		NCT07225504
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation	CNS demyelinating autoimmune disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis	Active, not recruiting	Phase 4	2026-05-29		NCT05090371